H.B. Fuller’s Valuations And Margins Driven By EV Momentum Earns It Analyst Conviction
Citigroup analyst Eric Petrie upgraded H.B. Fuller Co (NYSE:FUL) from Neutral to Buy and raised the price target from $72 to $85.…
Amazon’s Retail Strength Outshines AWS Slowdown, Analysts Are Raising Price Targets
E-commerce giant Amazon.com, Inc. (NASDAQ: AMZN) reported fourth-quarter financial results after market close Thursday.
Truist Remains Bullish On Lightspeed Commerce, Naming It An Acquisition Target; Credit Suisse Downgrades The Stock
Credit Suisse analyst Timothy Chiodo downgraded Lightspeed Commerce Inc (NYSE:LSPD) from Outperform to Neutral and lowered the price target from $21 to…
Why These 4 Starbucks Analysts Are Unphased By Q1 Earnings Miss
Shares of Starbucks Corporation (NASDAQ: SBUX) remained under pressure in early trading on Friday, after the company’s fiscal first-quarter earnings missed expectations.
Why These 4 Alphabet Analysts Are Divided Over Q4 Results
Shares of Alphabet Inc (NASDAQ: GOOGL) remained in the red in early trading on Friday.
JMP Securities on Alphabet
Why This Herbalife Nutrition Analyst Cannot Digest The Business Model
Herbalife Nutrition Ltd (NYSE: HLF) was gearing up to report its quarterly earnings on Feb. 14.
The company’s greatest challenge was its multi-level marketer (MLM) business model, according to BofA Securities.
‘Risk Of Overheating’: 4 Experts On Hot January Jobs Report, How The Fed Will React
The SPDR S&P 500 ETF Trust (NYSE: SPY) traded lower Friday after the Labor Department reported blowout U.S. jobs market numbers from January.
Big Tech Calls From Apple, Amazon, Alphabet Paint ‘Different Picture’ Than What Tech Bears Hoped For Says, Wedbush Analyst
Wedbush analyst Dan Ives said Thursday that calls from Apple Inc (NASDAQ: AAPL), Amazon.com, Inc (NASDAQ: AMZN) and Google parent Alphabet Inc (NASDAQ:
Johnson & Johnson’s Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
Cantor Fitzgerald is previewing its thoughts on a potential interim analysis for Johnson & Johnson’s (NYSE:JNJ) Phase 3 MARIPOSA study of Rybrevant (amivantamab)…